FGF12-AS2

Across TCGA pan-cancer cohorts, FGF12-AS2 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of FGF12-AS2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where FGF12-AS2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FGF12-AS2 is over-expressed in tumor, although a few such as PAAD and BRCA show the opposite, repressed pattern.

KIRC, KIRP, and LUAD are the cancer types where FGF12-AS2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FGF12-AS2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	+0.309	<.001	12	view →
KIRP	All	II,III,IV	+0.299	.001	9	view →
LUAD	All	II,III,IV	+0.376	<.001	7	view →
LUSC	Male	All	+0.363	<.001	4	view →
LIHC	All	All	+0.079	<.001	4	view →
PAAD	Male	All	−0.554	.017	2	view →
BRCA	All	All	−0.097	.028	2	view →
THCA	Female	All	+0.078	.048	2	view →
KICH	All	II,III,IV	+0.203	.045	1	view →
CHOL	All	All	+0.193	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

FGF12-AS2–KIRC

Open the KIRC breakdown →